Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gontivimab - Ablynx

Next Previous
Drug Profile

Gontivimab - Ablynx

Alternative Names: ALX-0171; Anti-RSV nanobody; VR 465

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ablynx
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Virus internalisation inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Respiratory syncytial virus infections

Most Recent Events

  • 19 Mar 2019 Ablynx withdraws a phase II trial prior to enrolment in Respiratory syncytial virus infections (In infants) in Australia, Belgium and Spain as the compny stopped development of ALX 0171 (NCT03468829)
  • 31 Dec 2018 Discontinued - Phase-II for Respiratory syncytial virus infections (In infants) in United Kingdom, Hungary, Spain, Slovakia, Belgium, Australia, Bulgaria, Estonia, Israel, Latvia, Malaysia, Philippines, Poland, Thailand, Germany, Lithuania, Chile, Croatia, Croatia, Colombia, Czech Republic, South Africa, Brazil (Inhalation) before December 2018 (Sanofi pipeline, February 2019)
  • 15 Nov 2018 Discontinued - Phase-II for Respiratory syncytial virus infections (In infants) in Japan (Inhalation) (NCT03418571)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top